

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 December 2007 (21.12.2007)

PCT

(10) International Publication Number
WO 2007/146489 A2


- (51) International Patent Classification:
A61B 5/00 (2006.01)
- (21) International Application Number:
PCT/US2007/066916
- (22) International Filing Date: 19 April 2007 (19.04.2007)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
11/422,417 6 June 2006 (06.06.2006) US
- (71) Applicant (for all designated States except US): **CARDIAC PACEMAKERS, INC.** [US/US]; 4100 Hamline Avenue North, St. Paul, Minnesota 55112-5798 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SHUROS, Allan C.** [US/US]; 1121 Colette Place, St. Paul, Minnesota 55116 (US). **KANE, Michael J.** [US/US]; 5173 Marquess Trail, Lake Elmo, Minnesota 55042 (US).
- (74) Agents: **CLISE, Timothy B.** et al.; Schwegman, Lundberg, Woessner & Kluth, P.A.P.O.Box 2938, Minneapolis, Minnesota 55402 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DEVICE FOR LYMPHATIC SYSTEM MONITORING



(57) Abstract: A device and method are disclosed for physiological monitoring of the lymphatic system. An implantable device is configured with a lymphatic sensor disposed in a lymphatic vessel for sensing pressure, flow, and/or the concentration of particular markers within the vessel. The device may be further configured to deliver appropriate therapy in accordance with the lymphatic monitoring.

WO 2007/146489 A2

DEVICE FOR LYMPHATIC SYSTEM MONITORING

CLAIM OF PRIORITY

5 Benefit of priority is hereby claimed to U.S. Patent Application Serial Number 11/422,417, filed on June 6, 2006, which application is herein incorporated by reference.

RELATED APPLICATIONS

10 This application is related to co-pending application Serial No. 11/422,423; Serial No. 11/422,414; Serial No. 11/422,418 and Serial No. 11/422,421, filed on June 6, 2006 and hereby incorporated by reference.

FIELD OF THE INVENTION

15 This invention pertains to methods and systems for diagnosing and treating disease with implantable devices.

BACKGROUND

20 The lymphatic system and the cardiovascular system are closely related structures that are joined by a capillary system. The lymphatic system is important to the body's defense mechanisms by filtering out organisms that cause disease and producing lymphocytes that attack foreign organisms and generate antibodies. It is also important for the distribution of fluids and nutrients in the body, because it drains excess fluids and protein from interstitial tissues. Lymph is the fluid that seeps outside
25 the blood vessels in interstitial spaces of body tissues and is then absorbed by lymphatic capillaries to flow back into the bloodstream through the lymphatic vessels. The terminal structures of the lymphatic vessels include the right lymphatic duct, which drains lymph fluid from the upper right quarter of the body above the diaphragm and down the midline, and the thoracic duct, located in the mediastinum of
30 the pleural cavity which drains the rest of the body. Through the flow of blood in and

out of arteries, into the veins, and through the lymph vessels and nodes, the body is able to eliminate the products of cellular breakdown and bacterial invasion.

SUMMARY

5 A device and method are disclosed for physiological monitoring of the lymphatic system. An implantable device is configured with a lymphatic sensor disposed in a lymphatic vessel for sensing pressure, flow, and/or the concentration of particular markers within the vessel. The device may be further configured to deliver appropriate therapy in accordance with the lymphatic monitoring.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the physical placement of an implanted monitoring device and attached lead.

15 Fig. 2 illustrates the components of an exemplary system for physiological monitoring of the lymphatic system.

Fig. 3 illustrates a block diagram of the components of an exemplary implantable monitoring device.

Fig. 4 illustrates an embodiment for delivering cardiac pacing therapy.

20

DETAILED DESCRIPTION

This disclosure relates to a device and method for monitoring lymphatic function. The lymphatic vessels are part of the body's circulatory system and serve as a pathway by which fluids can flow from the interstitial spaces into blood. Lymphatic vessels also communicate with lymph nodes and facilitate the body's immune function by transporting foreign antigens to the lymph nodes from the interstitial spaces. As described below, an implantable device may be used to monitor lymphatic function and thereby detect particular conditions such as increased inflammation and edema.

25 One of the functions performed by the lymphatic system is the conveying back to the blood of fluid and proteins exuded from the blood vessels into the interstitial space. Exuded fluid and proteins are absorbed by lymphatic capillaries and then flow

30

into the venous system through lymphatic vessels. The lymphatic system is normally very efficient at removing excess fluid from the interstitial space and is even able to maintain a slight negative pressure. Under certain conditions, however, the lymphatic system is so overwhelmed with fluid that a buildup occurs, referred to as edema.

5 When edema occurs, pressure and flow within the lymphatic vessels increases. As described below, an implantable device may be configured to measure these parameters and detect edema. The concentration of particular molecules in the lymphatic fluid may also be detected by the device in order to further characterize edema or detect other clinical states of interest. The device may also be configured to
10 deliver a specific therapy in response to the monitoring of lymphatic function, such as when edema is detected.

In one embodiment, a lymphatic function monitor may be incorporated as part of a cardiac pacing device configured to deliver cardiac resynchronization therapy (CRT) in which pacing pulses are used to overcome conduction deficits and cause the
15 heart to contract in a more coordinated manner (e.g., biventricular pacing). CRT is commonly used to treat patients with chronic heart failure. When chronic heart failure worsens, the decreased cardiac output causes diminished renal perfusion. The kidneys compensate for this by absorbing more salt and water from the renal filtrate which raises venous pressure. The increased venous pressure then results in edema when the
20 fluid buildup into the interstitial space overcomes the lymphatic system's ability to remove it. Edema due to heart failure may occur, for example, in the lung or in the extremities. In one embodiment, an implantable device configured to monitor lymphatic function may be further configured to initiate, increase, or modulate the delivery of CRT when edema is detected. The device could also be programmed to
25 adjust certain CRT parameters such as the atrio-ventricular delay interval when edema is detected.

Edema can also be caused by kidney disease or liver disease that results in decreased plasma proteins, particularly albumin. This causes increases osmotic pressure that forces more fluid from the blood capillaries into the interstitium. In
30 another embodiment, the device is configured to deliver an appropriate medication

when edema is detected (e.g., an ACE inhibitor or angiotensin receptor blocker for the treatment of kidney disease.)

The composition of lymphatic fluid may also be monitored to determine if particular clinical states exist. For example, the concentration of cytokines and immunoglobulins may be used to assess certain autoimmune diseases and cancer. When the concentration of such substances reaches a particular level, the device may then be configured to deliver an appropriate medication.

Fig. 1 shows an exemplary physical placement of an implantable monitoring device as described herein. In one embodiment, an implantable monitoring device 105 is placed subcutaneously on the patient's chest or abdomen, similar to a standard cardiac pacemaker. The monitoring device is connected to one or more leads 110, each having a distal member that incorporates an electrode or sensor for sensing physiological parameter(s) related to lymphatic function, referred to herein as a lymphatic sensor. The lead is positioned within the lymphatic system using a venous approach which involves initial entry into the venous blood system. In the embodiment depicted in Fig. 1, the lead 110 passes subcutaneously from the device housing 130 to a point of venous access in the upper chest or neck such as the subclavian vein. The lead is then guided into the thoracic duct ostium using standard fluoroscopy techniques and positioned at a selected location within the lymphatic system. An alternative implantation approach includes placing the lymphatic sensor using a direct surgical approach.

Fig. 2 shows an exemplary monitoring system. The pulse monitoring device 105 includes a hermetically sealed housing 130 that is placed subcutaneously or submuscularly in a patient's chest or other convenient location as noted above. The housing 130 may be formed from a conductive metal, such as titanium, and may serve as an electrode for delivering electrical stimulation with a unipolar lead. A header 140, which may be formed of an insulating material, is mounted on the housing 130 for receiving the leads 110 which are electrically connected to the circuitry within the housing. Contained within the housing 130 is the electronic circuitry 132 for providing the functionality to the device as described herein which may include a

power supply, monitoring circuitry, therapy circuitry, and a programmable electronic controller for controlling the operation of the device.

Fig. 3 illustrates exemplary components of the electronic circuitry 132 depicted in Fig. 2. A controller 135 is provided which may be made up of discrete circuit elements but is preferably a processing element such as a microprocessor together with associated memory for program and data storage which may be programmed to perform algorithms for delivering therapy. (As the terms are used herein, "circuitry" and "controller" may refer either to a programmed processor or to dedicated hardware components configured to perform a particular task.) The controller is interfaced to monitoring circuitry 136 from which it receives data generated by one or more lymphatic sensors 137. The monitoring circuitry may include, for example, circuitry for amplification, filtering, and/or analog-to-digital conversion of voltages generated by a lymphatic sensor.

In one embodiment, the lymphatic sensor 137 is a flow or pressure sensor for sensing conditions within a lymphatic vessel that indicate edema may be present. As noted above, edema may be diagnosed when the lymphatic vessels are overwhelmed with fluid due to, for example, elevated venous pressure caused by heart failure and renal compensation thereof, kidney disease, or liver disease. Under such conditions, the pressure and/or flow of lymph within the lymphatic vessels may be increased. In another embodiment, the lymphatic sensor is a chemo-sensor designed to generate a voltage proportional to the concentration of a particular chemical species. The chemo-sensor may be used to provide the controller an indication of the concentration of a particular molecule in the lymphatic fluid that is of interest, referred to as a marker. Examples of markers whose concentrations may be of diagnostic value include immunoglobulins, cytokines, or specific proteins that could be used to characterize a particular disease state. Such chemo-sensors may use immobilized antibodies with binding affinities specific for the different marker antigens. Upon formation of an Ab-Ag complex between the antibody and the marker, the chemo-sensor may produce an electrical signal by, for example, incorporating a piezoelectric transducer that responds

to mechanical stresses induced by the Ab-Ag complex or a transducer that responds to potential changes resulting from the Ab-Ag complex.

In another embodiment, the lymphatic sensor is a stretch or volume sensor that monitors the degree of stretch or change in volume within a lymphatic vessel using
5 impedance, ultrasonics, acoustic, capacitance, inductance, or optical-type instruments. In another embodiment, the lymphatic sensor is a pulsatile rate sensor using impedance, ultrasonics, acoustic, piezoelectric, piezoresistive, capacitance, inductance, or optical type instruments to monitor pulsatile flow within a lymphatic vessel or a
10 pulsatile contractility sensor that measures intensity of peristaltic wave motion using impedance, ultrasonics, acoustic, capacitance, inductance, or optical type instruments. In another embodiment, the lymphatic sensor is a density sensor for detecting the concentration of dissolved and suspended particulates in the lymph fluid using an optical, acoustic, or electrical instrument. In another embodiment, the lymphatic
15 sensor is a cell counting sensor that detects the density of lymphocytes in the lymph fluid.

In the embodiment illustrated in Fig. 3, the controller 135 is also interfaced to therapy circuitry 140 in order to control the delivery of therapy by the device in response to conditions sensed by the monitoring circuitry. The therapy circuitry 135 may include circuitry for delivery of one or more therapy modalities such as cardiac
20 resynchronization therapy, neural stimulation, and drug therapy. In one embodiment, shown in Fig. 4, the device includes circuitry for delivering bradycardia cardiac pacing and/or cardiac resynchronization therapy and includes pulse generation circuitry 140, cardiac sensing circuitry 142, and pacing/sensing electrodes 111 electrically connected to the device by leads (i.e., intravenous leads such as shown in Fig. 1) adapted for
25 disposition in the heart. In another embodiment, the device includes a drug delivery device 145 actuated by the therapy circuitry that may be used to deliver medication in response detection of particular conditions. Such medications could include anti-inflammatory drugs, cancer chemotherapeutic agents, diuretics, or cardiac drugs.

Also interfaced to the controller in Fig. 3 is a telemetry transceiver 150 capable
30 of communicating with an external programmer or a remote monitoring device 190 as

illustrated in Fig. 2. An external programmer wirelessly communicates with the device 105 and enables a clinician to receive data and modify the programming of the controller. A remote monitoring device similarly communicates with the device 105 and is further interfaced to a network 195 (e.g., an internet connection) for communicating with a patient management server 196 that allows clinical personnel at remote locations to receive data from the remote monitoring device as well as issue commands. The controller may be programmed such when particular conditions are detected by the monitoring circuitry (such as when a measured parameter exceeds or falls below a specified limit value), the device transmits an alarm message to the remote monitoring device and to the patient management server to alert clinical personnel.

In order to implant a lead incorporating a lymphatic sensor(s) into a selected location within lymphatic vessel, the lymphatic system may be visualized using lymphangiography. In this technique, dye is injected into the subcutaneous tissue of an extremity such as the foot, or other peripheral lymph vessel, and the lymphatic system drains the dye making the lymphatic vessels visible. A lymphatic vessel is cannulated, and radiopaque contrast is injected to illuminate major lymph vessels including the thoracic duct and its ostium into the subclavian vein. A catheter or the lead may then be guided into the thoracic duct ostium via the venous system using fluoroscopy techniques and positioned at a selected location within the lymphatic system. Initial cannulation of the lymph ostium with a guide wire or catheter may be achieved through the left or right subclavian vein, the left jugular veins, the epigastric/mammary veins or the femoral veins. In order to facilitate navigation through the lymphatic vessels and position the sensor at a selected anatomical location, an overlapping technique may be employed whereby fluoroscopic images produced by the injected dye are used in conjunction with anatomical images of the patient produced by other modalities such as conventional x-ray, CAT scans, MRI scans, or ultrasonic scans. The fluoroscopic image may be overlaid with the anatomical image and the lead then guided to the selected location.

To implant the lead, a catheter or the lead by itself may be introduced into the venous system and from there into the thoracic duct ostium using conventional over-the-wire techniques that employ a guide wire. The guide wire is manually or mechanically pushed and manipulated to guide its travel and upon which catheters and/or leads may be advanced. A stereotaxis technique in which external magnets or other means are used to guide the catheter may also be used to improve maneuverability and precision as well as provide increased safety. An example of this technique is described in U.S. Patent No. 6,475,223, hereby incorporated by reference. Once the catheter or lead is in the lymphatic system, it must also traverse valves in the lymphatic vessels whose function is to allow flow of lymphatic fluid in only one direction to the thoracic duct. In the case where a catheter is employed, as the catheter is guided through a vessel to one of these valves, the catheter may incorporate a vacuum system to open the valves. When the vacuum system is actuated, it draws negative pressure to create a pressure gradient that opens the valve. An alternative technique for opening lymphatic valves involves using a catheter incorporating a compliant balloon on its distal tip. When the catheter reaches a lymphatic valve, the balloon is inflated to mechanically dilate the vessel which opens the valve and allows a wire or the catheter to pass through. In still another technique, the catheter incorporates an electrode at its tip that is used to cause smooth muscle contraction of the lymphatic vessel. Such smooth muscle contraction can create a pressure gradient that opens the valve and allows the catheter to advance past the valve.

Although the invention has been described in conjunction with the foregoing specific embodiments, many alternatives, variations, and modifications will be apparent to those of ordinary skill in the art. Such alternatives, variations, and modifications are intended to fall within the scope of the following appended claims.

What is claimed is:

1. A device, comprising:
monitoring circuitry contained within an implantable housing;
5 a lead electrically connected to the monitoring circuitry that is adapted for
implantation into a lymphatic vessel, the lead having a lymphatic sensor incorporated
therein for sensing a physiological parameter related to lymphatic function;
a controller interfaced to the monitoring circuitry for processing sensing signals
generated by the lymphatic sensor.
10
2. The device of claim 1 wherein the lymphatic sensor is a pressure sensor.
3. The device of claim 1 wherein the lymphatic sensor is a flow sensor.
- 15 4. The device of claim 1 wherein the lymphatic sensor is a chemo-sensor for
generating a voltage proportional to the concentration of a particular chemical species
in the lymphatic fluid.
5. The device of claim 1 further comprising a telemetry transceiver interfaced to
20 the controller for enabling wireless communication with the controller.
6. The device of claim 5 wherein the controller is programmed to transmit an
alarm message via the telemetry transceiver if a value sensed by the lymphatic sensor
reaches a specified limit value.
25
7. The device of claim 1 further comprising:
therapy circuitry interfaced to the controller; and,
wherein the controller is programmed to deliver therapy based upon sensing
signals generated by the lymphatic sensor.
30

8. The device of claim 7 wherein the therapy circuitry comprises:
cardiac pacing circuitry, including pulse generation circuitry and cardiac
sensing circuitry;
one or more leads with pacing/sensing electrodes electrically connected to the
5 cardiac pacing circuitry; and,
wherein the controller is programmed to deliver cardiac resynchronization
therapy based upon sensing signals generated by the lymphatic sensor.
9. The device of claim 8 wherein the controller is programmed to initiate, or
10 increase, the delivery of cardiac resynchronization therapy upon sensing a lymphatic
flow or pressure value indicative of edema.
10. The device of claim 8 wherein the controller is programmed to adjust one or
more cardiac resynchronization parameters upon sensing a lymphatic flow or pressure
15 value indicative of edema.
11. A method, comprising:
implanting a housing containing monitoring circuitry;
implanting a lead electrically connected to the monitoring circuitry into a
20 lymphatic vessel, the lead having a lymphatic sensor incorporated therein for sensing a
physiological parameter related to lymphatic function;
processing sensing signals generated by the lymphatic sensor via the
monitoring circuitry.
- 25 12. The method of claim 11 wherein the lymphatic sensor is a pressure sensor.
13. The method of claim 11 wherein the lymphatic sensor is a flow sensor.

14. The method of claim 11 wherein the lymphatic sensor is a chemo-sensor for generating a voltage proportional to the concentration of a particular chemical species in the lymphatic fluid.

5 15. The method of claim 11 further comprising transmitting an alarm message via a telemetry transceiver if a value sensed by the lymphatic sensor reaches a specified limit value.

16. The method of claim 11 further comprising delivering therapy based upon
10 sensing signals generated by the lymphatic sensor.

17. The method of claim 16 further comprising delivering cardiac
resynchronization therapy based upon sensing signals generated by the lymphatic
sensor.

15

18. The method of claim 17 further comprising initiating or increasing the delivery
of cardiac resynchronization therapy upon sensing a lymphatic flow or pressure value
indicative of edema.

20 19. The method of claim 17 further comprising adjusting one or more cardiac
resynchronization parameters upon sensing a lymphatic flow or pressure value
indicative of edema.




Fig. 1




Fig. 2




Fig. 3




Fig. 4

专利名称(译)	用于淋巴系统监测的装置		
公开(公告)号	EP2029003A2	公开(公告)日	2009-03-04
申请号	EP2007797246	申请日	2007-04-19
[标]申请(专利权)人(译)	心脏起搏器股份公司		
申请(专利权)人(译)	心脏起搏器, INC.		
当前申请(专利权)人(译)	心脏起搏器, INC.		
[标]发明人	SHUROS ALLAN C KANE MICHAEL J		
发明人	SHUROS, ALLAN C. KANE, MICHAEL J.		
IPC分类号	A61B5/00 A61B5/03 A61B5/07 A61N1/365		
CPC分类号	A61B5/03 A61B5/0031 A61B5/076 A61B5/14546 A61B5/415 A61B5/418 A61B5/4839 A61N1/3627 A61N1/36514		
代理机构(译)	PETERREINS, FRANK		
优先权	11/422417 2006-06-06 US		
外部链接	Espacenet		

摘要(译)

公开了一种用于淋巴系统的生理监测的装置和方法。可植入装置配置有淋巴传感器，淋巴传感器设置在淋巴管中，用于感测血管内的特定标记物的压力，流量和/或浓度。该装置可进一步配置成根据淋巴监测递送适当的治疗。